ER-ɑ36, a Novel Therapeutic Target for Triple-negative Breast Cancer
Abstract
According to the molecular classification, triple-negative breast cancer (TNBC) belongs to the basal-like type of breast cancer that is characterized by lacking expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). There are currently no effective therapeutic options for TNBC. Recently, a novel isoform of ER-a, ER-a36, has been identified and cloned that plays a critical role in the malignant growth of TNBC. Here, we review and update the biological functions of ER-a36 in the cross talks with growth factor receptors, maintenance of cancer stem/progenitor cells and antiestrogen resistance of TNBC. ER-a36 as a potential therapeutic target in TNBC will also be discussed.
Keywords
Full Text:
Subscribers OnlyReferences
Foulkes, W.D., I.E. Smith ,J.S. Reis-Filho, Triple-negative breast cancer. N Engl J Med, 2010. 363(20): p. 1938-48.
Nowacka-Zawisza, M. ,W.M. Krajewska, [Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches]. Postepy Hig Med Dosw (Online), 2013. 67: p. 1090-7.
Yadav, B.S., P. Chanana ,S. Jhamb, Biomarkers in triple negative breast cancer: A review. World J Clin Oncol, 2015. 6(6): p. 252-63.
Wang, Z., X. Zhang, P. Shen, B.W. Loggie, Y. Chang ,T.F. Deuel, Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun, 2005. 336(4): p. 1023-7.
Wang, Z., X. Zhang, P. Shen, B.W. Loggie, Y. Chang ,T.F. Deuel, A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A, 2006. 103(24): p. 9063-8.
Vranic, S., Z. Gatalica, H. Deng, S. Frkovic-Grazio, L.M. Lee, O. Gurjeva, et al., ER-alpha36, a novel isoform of ER-alpha66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast. J Clin Pathol, 2011. 64(1): p. 54-7.
Zou, Y., L. Ding, M. Coleman ,Z. Wang, Estrogen receptor-alpha (ER-alpha) suppresses expression of its variant ER-alpha 36. FEBS Lett, 2009. 583(8): p. 1368-74.
Lee, L.M., J. Cao, H. Deng, P. Chen, Z. Gatalica ,Z.Y. Wang, ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res, 2008. 28(1B): p. 479-83.
Shi, L., B. Dong, Z. Li, Y. Lu, T. Ouyang, J. Li, et al., Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol, 2009. 27(21): p. 3423-9.
Pelekanou, V., G. Notas, M. Kampa, E. Tsentelierou, J. Radojicic, G. Leclercq, et al., ERalpha36, a new variant of the ERalpha is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines. Steroids, 2012. 77(10): p. 928-34.
Tu, B.B., S.L. Lin, L.Y. Yan, Z.Y. Wang, Q.Y. Sun ,J. Qiao, ER-alpha36, a novel variant of estrogen receptor alpha, is involved in EGFR-related carcinogenesis in endometrial cancer. Am J Obstet Gynecol, 2011. 205(3): p. 227 e1-6.
Jiang, H., R. Teng, Q. Wang, X. Zhang, H. Wang, Z. Wang, et al., Transcriptional analysis of estrogen receptor alpha variant mRNAs in colorectal cancers and their matched normal colorectal tissues. J Steroid Biochem Mol Biol, 2008. 112(1-3): p. 20-4.
Wang, J., J. Li, R. Fang, S. Xie, L. Wang ,C. Xu, Expression of ERalpha36 in gastric cancer samples and their matched normal tissues. Oncol Lett, 2012. 3(1): p. 172-175.
Schwartz, N., R.A. Chaudhri, A. Hadadi, Z. Schwartz ,B.D. Boyan, 17Beta-estradiol promotes aggressive laryngeal cancer through membrane-associated estrogen receptor-alpha 36. Horm Cancer, 2014. 5(1): p. 22-32.
Wang, Q., W. Zhang, J. Yang, Y.L. Liu, Z.X. Yan, Z.J. Guo, et al., High ERalpha36 Expression Level and Membrane Location Predict Poor Prognosis in Renal Cell Carcinoma. Medicine (Baltimore), 2015. 94(26): p. e1048.
Miceli, V., L. Cocciadiferro, M. Fregapane, M. Zarcone, G. Montalto, L.M. Polito, et al., Expression of wild-type and variant estrogen receptor alpha in liver carcinogenesis and tumor progression. OMICS, 2011. 15(5): p. 313-7.
Baulieu, E.E., N. Binart, F. Cadepond, M.G. Catelli, B. Chambraud, J. Garnier, et al., Receptor-associated nuclear proteins and steroid/antisteroid action. Ann N Y Acad Sci, 1990. 595: p. 300-15.
Segars, J.H. ,P.H. Driggers, Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes. Trends Endocrinol Metab, 2002. 13(8): p. 349-54.
Lin, S.L., L.Y. Yan, X.T. Zhang, J. Yuan, M. Li, J. Qiao, et al., ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One, 2010. 5(2): p. e9013.
Zhang, X., H. Deng ,Z.Y. Wang, Estrogen activation of the mitogen-activated protein kinase is mediated by ER-alpha36 in ER-positive breast cancer cells. J Steroid Biochem Mol Biol, 2014. 143: p. 434-43.
Kang, L., X. Zhang, Y. Xie, Y. Tu, D. Wang, Z. Liu, et al., Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol, 2010. 24(4): p. 709-21.
Zhang, X.T., L.G. Kang, L. Ding, S. Vranic, Z. Gatalica ,Z.Y. Wang, A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene, 2010. 30(7): p. 770-780.
Lin, S.L., L.Y. Yan, X.W. Liang, Z.B. Wang, Z.Y. Wang, J. Qiao, et al., A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Reprod Biol Endocrinol, 2009. 7: p. 102.
Ohshiro, K., A.M. Schwartz, P.H. Levine ,R. Kumar, Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling. PLoS One, 2012. 7(1): p. e30725.
Tong, J.S., Q.H. Zhang, Z.B. Wang, S. Li, C.R. Yang, X.Q. Fu, et al., ER-alpha36, a novel variant of ER-alpha, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCdelta/ERK pathway. PLoS One, 2010. 5(11): p. e15408.
Chaudhri, R.A., R. Olivares-Navarrete, N. Cuenca, A. Hadadi, B.D. Boyan ,Z. Schwartz, Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-alpha36 (ERalpha36). J Biol Chem, 2012. 287(10): p. 7169-81.
Jordan, N.J., J.M. Gee, D. Barrow, A.E. Wakeling ,R.I. Nicholson, Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat, 2004. 87(2): p. 167-80.
Gu, Y., T. Chen, E. Lopez, W. Wu, X. Wang, J. Cao, et al., The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors. J Transl Med, 2014. 12: p. 16.
Zhang, X. ,Z.Y. Wang, Estrogen receptor-alpha variant, ER-alpha36, is involved in tamoxifen resistance and estrogen hypersensitivity. Endocrinology, 2013. 154(6): p. 1990-8.
Razandi, M., A. Pedram, S.T. Park ,E.R. Levin, Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem, 2003. 278(4): p. 2701-12.
Song, R.X., Z. Zhang, Y. Chen, Y. Bao ,R.J. Santen, Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology, 2007. 148(8): p. 4091-101.
Zhang, X.T., L.G. Kang, L. Ding, S. Vranic, Z. Gatalica ,Z.Y. Wang, A positive feedback loop of ER-alpha36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene, 2011. 30(7): p. 770-80.
Migliaccio, A., G. Castoria, M. Di Domenico, A. de Falco, A. Bilancio, M. Lombardi, et al., Sex steroid hormones act as growth factors. J Steroid Biochem Mol Biol, 2002. 83(1-5): p. 31-5.
Shupnik, M.A., Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene, 2004. 23(48): p. 7979-89.
Deng, H., X.T. Zhang, M.L. Wang, H.Y. Zheng, L.J. Liu ,Z.Y. Wang, ER-alpha36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells. PLoS One, 2014. 9(2): p. e88034.
Zhang, J., G. Li, Z. Li, X. Yu, Y. Zheng, K. Jin, et al., Estrogen-independent effects of ER-alpha36 in ER-negative breast cancer. Steroids, 2012. 77(6): p. 666-73.
Kang, L., Y. Guo, X. Zhang, J. Meng ,Z.Y. Wang, A positive cross-regulation of HER2 and ER-alpha36 controls ALDH1 positive breast cancer cells. J Steroid Biochem Mol Biol, 2011. 127(3-5): p. 262-8.
Guo, M., M. Wang, H. Deng, X. Zhang ,Z.Y. Wang, A novel anticancer agent Broussoflavonol B downregulates estrogen receptor (ER)-alpha36 expression and inhibits growth of ER-negative breast cancer MDA-MB-231 cells. Eur J Pharmacol, 2013. 714(1-3): p. 56-64.
Morris, G.J., S. Naidu, A.K. Topham, F. Guiles, Y. Xu, P. McCue, et al., Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer, 2007. 110(4): p. 876-84.
Wallacides, A., A. Chesnel, H. Ajj, M. Chillet, S. Flament ,H. Dumond, Estrogens promote proliferation of the seminoma-like TCam-2 cell line through a GPER-dependent ERalpha36 induction. Mol Cell Endocrinol, 2012. 350(1): p. 61-71.
Yin, L. ,Z.Y. Wang, Roles of the ER-alpha36-EGFR/HER2 positive regulatory loops in tamoxifen resistance. Steroids, 2016. 111: p. 95-9.
Howell, A., C.K. Osborne, C. Morris ,A.E. Wakeling, ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer, 2000. 89(4): p. 817-25.
Zhang, X., L. Ding, L. Kang ,Z.Y. Wang, Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells. PLoS One, 2012. 7(1): p. e30174.
Yin, L., X.T. Zhang, X.W. Bian, Y.M. Guo ,Z.Y. Wang, Disruption of the ER-alpha36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells. PLoS One, 2014. 9(9): p. e107369.
DOI: http://dx.doi.org/10.18103/imr.v3i3.388
Refbacks
- There are currently no refbacks.